[A21-135] AR101 (Peanut allergy) - Benefit assessment according to §35a Social Code Book V
Last updated 08.04.2022
Project no.:
A21-135
Commission:
Commission awarded on 15.10.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Immune system and infections
Patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy
Proof of lesser benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A22-29 | AR101 (peanut allergy) - Addendum to Commission A21-135 | Commission completed |
Federal Joint Committee (G-BA)
2022-04-07 A G-BA decision was published.